Document |
Document Title |
WO/2011/006610A1 |
The present invention provides novel and advantageous processes for preparing and purifying pharmaceuticals The processes comprise a nucleophilic reaction wherein a modified leaving group LM, which has increased lipophilicity, of a vecto...
|
WO/2011/008247A1 |
The present invention relates novel flavin derivatives and other flavin derivatives, their use and compositions for use as riboswitch ligands and/or anti-infectives. The invention also provides method of making novel flavin derivatives.
|
WO/2011/007123A1 |
In an embodiment, the present invention provides a process for preparing (-)-6-(4- aminophenyl)-5-methylpyridazin-3-(2H)-one, which process comprises: a) reacting racemic 6-(4-aminophenyl)-4,5-dihydro-5-methyl-3-(2H)-pyridazinone of form...
|
WO/2010/145790A1 |
The present invention relates to propargyloxybenzamide derivatives, their processes of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic ...
|
WO/2010/131147A1 |
The present invention relates to compounds of the formula (I): to pharmaceutically acceptable salts therefore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compos...
|
WO/2010/126104A1 |
Disclosed is a novel pyridazinone compound having an activity of inhibiting P2X7 receptor that is a kind of purine receptor, which is useful in preventing, treating or ameliorating diseases relating to inflammation or immunity. Specifica...
|
WO/2010/122082A1 |
Compounds having the formula I wherein R1, R2, R3, R4, R5a, R5b, R5c and R6 are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting ...
|
WO/2010/116084A1 |
The subject of the present invention is compounds corresponding to the formula (I) in which: X represents a divalent (C2-C5)alkylene radical which is unsubstituted or substituted one or more times by an Alk group; R1 represents a phenyl,...
|
WO/2010/113986A1 |
A pyridazinone compound represented by formula (I) has a harmful arthropod pests control activity and is therefore effective for the control of harmful arthropod pests.
|
WO/2010/112177A1 |
The present invention relates to aminopyridine and aminopyridazine derivatives of the general formula (I), where R1, X, W and Q have the meanings as indicated in the description, to a plurality of methods for the production thereof and t...
|
WO/2010/114493A1 |
The present invention relates to a compound of formula (I). Provided is also a method of killing a cell that comprises administering the compound of formula (I). Provided is also a method of treating cancer or diabetes in a mammal that c...
|
WO/2010/102717A1 |
The present application relates to novel alkyl carboxylic acids, having an oxo-substituted aza-heterocyclical partial structure, to a method for producing same, to the use thereof for treating and/or preventing disease, and to the use th...
|
WO/2010/104217A1 |
A pyridazinone compound represented by formula (I) wherein R1 represents a C1-6 alkyl group or a (C1- 6 alkyloxy) C1 - 6 alkyl group, R2 and R3 represent hydrogen or a C1 -6 alkyl group, W represents halogen, etc., Z1 represents a C1- 6 ...
|
WO/2010/097374A1 |
The invention relates to the compounds of the general formula (I) wherein n, R1, R2, R3, R4, R5, R6, R7 and R8 are defined as described in the description, to enantiomers thereof, to diastereomers thereof, to mixtures and salts thereof, ...
|
WO/2010/097372A1 |
The invention relates to the compounds of the general formula (I) wherein n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and X are defined as described below, to enantiomers thereof, to diastereomers thereof, to mixtures and salts there...
|
WO/2010/094955A1 |
A compound formula (IA) or (IB), or a pharmaceutically acceptable thereof; wherein the substituents are defined as in the claims, and their use as P38 MAP kinase.
|
WO/2010/082858A2 |
The invention is related to a method for preparing 5-amino-2,3-dihydrophthalazine-1,4-dione salt with alkali metals of the formula Il wherein 5-nitro-2,3- dihydrophthalazine-1,4-dione is solved in water solution of MOH1 where M has the b...
|
WO/2010/078912A1 |
The invention relates to pyridazinones of the formula (I) as herbicides and insecticides. In said formula (I), A, B, G, X1, Y, and Z are radicals such as hydrogen, organic radicals such as alkyls, and other radicals such as halogens, nit...
|
WO/2010/077275A1 |
Cyclohexane derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in t...
|
WO/2010/074272A1 |
Provided is a method whereby a heteroaromatic ring aryl can be very rapidly methylated at a high yield. In an N-alkyl-2-pyrrolidinone, a heteroaromatic ring aryltrialkylstannan is cross-coupled with methyl iodide in the presence of a pal...
|
WO/2010/072598A1 |
Compounds having the formula (I) wherein A, R1, R2, R3, R4a, R4b, R4c, R5, R6, R7a, R7b, Ar1, Rc, Rd, Re, Rf, X, n and p are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods ...
|
WO/2010/069525A1 |
The invention relates to the phenyl-substituted pyridazinones of formula (I) for use as herbicides and insecticides. In formula (I), A, B, G, X, Y and Z represent groups such as hydrogen, organic groups such as alkyl, and other groups su...
|
WO/2010/069526A1 |
The invention relates to the phenyl-substituted pyridazinones of formula (I) for use as herbicides and insecticides. In formula (I), A, B, G, X, Y and Z represent groups such as hydrogen, organic groups such as alkyl, and other groups su...
|
WO/2010/058995A1 |
Provided is an electroluminescent device comprising an organic layer interposed between an anode and a cathode on a substrate, wherein the organic layer includes an electroluminescent layer containing one or more dopant compound (s), and...
|
WO/2010/050779A1 |
Provided are novel organic electroluminescent compounds, and organic electroluminescent devices and organic solar cells comprising the same. The organic electroluminescent compounds according to the present invention exhibit high luminou...
|
WO/2010/045580A1 |
This disclosure relates to sphingosine-1 -phosphate (SlP) receptor antagonists, compositions comprising the SlP receptor antagonists and methods for using and processes for making the SlP receptor antagonists. In particularly, this discl...
|
WO/2010/044054A1 |
The invention relates to novel phenethylamide derivatives and their heterocyclic analogues of formula (I), wherein A, B, R1, R2 and R3 are as described in the application, and to the use of such compounds, or of pharmaceutically acceptab...
|
WO/2010/042649A2 |
The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A4, L, R...
|
WO/2010/036553A1 |
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein R1, R2, R3, R4, X, Y and m are as defined in the disclosure. Also disclosed are compositions containing the compounds o...
|
WO/2010/029379A1 |
The present invention relates to compounds of general formula (i) having an oxime moiety or a pharmaceutically acceptable salt, hydrate or solvate thereof and its use for inhibiting semicarbazide-sensitive amine oxidase (SSAO), also know...
|
WO/2010/028051A2 |
The present invention generally relates to substituted heterocyclic mercaptosulfonamide compounds, precursors, and derivatives as well as methods for the preparation of and pharmaceutical compositions comprising these compounds. These co...
|
WO/2010/019417A2 |
Disclosed are small molecule inhibitors which are useful in treating various diseases and conditions involving chymase (formula I). Also disclosed are pharmaceutical compositions, methods of using and making the same.
|
WO/2010/006940A1 |
Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein A and R1 to R3 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.
|
WO/2010/003624A2 |
Heterocyclic derivatives, processes for their preparation, medicaments comprising these compounds, and the use thereof. The invention relates to compounds of the formula I in which the radicals R1, R2, R3, R4, W, A, B, D, E, G, L, M, R, ...
|
WO/2010/004215A2 |
The present invention relates to compounds having the formula (I) where: - R1 is: a substituted or non-substituted phenyl; a substituted or non-substituted naphthyl; a substituted or non-substituted pyridyl; a substituted or non-substitu...
|
WO/2010/000456A1 |
The present invention is concerned with novel substituted 6-(1-piperazinyl)-pyridazines of Formula (I) wherein R1, R2, R3 and X have the meaning defined in the claims, having 5 -HT6- antagonistic properties. The invention further relates...
|
WO/2009/157425A1 |
Disclosed is a composition comprising a compound having a pyridazine ring structure and a phosphorescent compound.
|
WO/2009/146648A1 |
Amide compounds, preparation methods and uses thereof. The structure of the compounds is represented as the general formula (I), in which the definitions of substituents are illuminated as description. The present amide compounds have br...
|
WO/2009/141291A1 |
The present invention relates to heteroarylylmethyl sulfonamides of formula (I) wherein B, E, Ra, n, R, A, Y and Cy are as defined in the claims, to the N-oxides, and salts thereof and their use for combating harmful fungi, and also to c...
|
WO/2009/136191A1 |
The invention relates to chemical compounds of formula (I): or pharmaceutically acceptable salts thereof which possess CSF-IR kinase inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of tre...
|
WO/2009/131947A2 |
The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administerin...
|
WO/2009/127338A1 |
The present invention relates to novel carboxylic acid derivates of the formula (I), having an oxo-substituted azaheterocyclic partial structure, method for the production thereof, use thereof for treating and/or preventing illnesses and...
|
WO/2009/129267A2 |
Pleckstrin homology domain binding compounds, pharmaceutical compositions including such compounds, and methods for their use are described herein.
|
WO/2009/124903A1 |
The present invention relates to pyridazinylmethyl sulfonamides of formula (I) wherein Ra, n, R1, R2, R3, A, Y and Het are as defined in the claims, to the N-oxides, and salts thereof and their use for combating harmful fungi, and also t...
|
WO/2009/079797A9 |
The invention relates to a compound of Formula (I) and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, E-isomer, Z-isomer, or combination thereof, wherein X is selected from S or O; R5 is selected from ...
|
WO/2009/114994A1 |
Derivatives of 6-(3-(trifluoromethyl)phenyl)pyridazin-3(2H)-one having the following formula (I) are used for the manufacture of medicament for anti-tumour, particularly anti-liver cancer.
|
WO/2009/114993A1 |
Pyridazinones of formula I, which have a mother nucleus of 6-[3-(trifluoromethyl)phenyl] pyridazin-3(2H)-one, the preparation and the use in manufacturing medicaments of treating tumor thereof. Particularly, the use of such compounds in ...
|
WO/2009/112461A1 |
This invention relates to novel triaryl derivatives derivatives, formula (I), a stereoisomer thereof or a mixture of its stereoisomers, or a pharmaceutically acceptable salt thereof, wherein all of X, Y and Z represent CH; or one or two ...
|
WO/2009/103478A1 |
The present invention relates to pyridone and pyridazinone derivatives as listed in claim 1 including their salts. Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention....
|
WO/2009/097306A1 |
The present invention is directed to compounds having histamine H3 antagonist activity, as well as methods of their use and preparation.
|